



6

SEQUENCE LISTING

<110> Rybczynski, Philip
et al.

<120> BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES

<130> pm431, patin2.1

<140>

<141>

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 1

cattttgtga gttttctagg attattcttt tctcttgga agaaagt

47

<210> 2

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 2

atgtaggtt tggccatgcc tttctcttgg aaagaaagt

39

<210> 3

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 3

cctctcgttt tctctttatg gttttctctt ggaaagaaag t

41

<210> 4

<211> 47

<212> DNA

<213> Artificial Sequence

COPY OF PAPERS
ORIGINALLY FILED

<220>
 <223> Description of Artificial Sequence: primer

 <400> 4
 gcttatgctc ttcataaac tctcgtgggt tctcttggaa agaaagt 47

 <210> 5
 <211> 46
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer

 <400> 5
 ccaggtagct acaaaagcat cacatttagg cataggaccc gtgtct 46

 <210> 6
 <211> 50
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer

 <400> 6
 gccactcct acttctttca tataatcatt taggcatagg acccgtgtct 50

 <210> 7
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer

 <400> 7
 agccactttc ctggtggcaa atttaggcat aggaccgtg tct 43

 <210> 8
 <211> 45
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer

 <400> 8
 catccccatt cacactgatg atctttaggc ataggaccg tgtct 45

 <210> 9
 <211> 48

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 9
gtaccaggac acccccatct aagggttttta ggcattaggac ccgtgtct

48

<210> 10
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 10
ggttgatttt ccatccatt tctgcacatt ttaggcattag gaccctgtc t

51

<210> 11
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 11
gcattccacc accagtttat catttttaggc ataggaccgc tgtct

45

<210> 12
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 12
gcgaacttca gtccagggtca acgtcccttg ttaggcata ggaccctgt ct

52

<210> 13
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 13
tcccacagaa tggtgtagag ttcaatttta ggcattaggac ccgtgtct

48

<210> 14
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 14
aaaacaacaa tatctttttg aacaatatat ttaggcata gacccgtgtc t 51

<210> 15
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 15
tcaaagtttt cactggagac aagttt 26



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/990,461	11/21/2001	Thomas P. Burris	ORT-1527

000027777
AUDLEY A. CIAMPORCERO JR.
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003

RECEIVED

MAR 28 2002

CONFIRMATION NO. 4152

FORMALITIES LETTER

0000000007703933

Date Mailed: 03/25/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR-AMINO ACID SEQUENCE
DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice **MUST** be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY